Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 9(2020), 1 vom: 15. Dez., Seite 757-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Juan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.04.2020 Date Revised 13.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2020.1746200 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308138686 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308138686 | ||
| 003 | DE-627 | ||
| 005 | 20231225131111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2020.1746200 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308138686 | ||
| 035 | |a (NLM)32228222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Renin-angiotensin system | |
| 650 | 4 | |a angiotensin II type1 receptor blockers | |
| 650 | 4 | |a angiotensin-converting enzyme inhibitors | |
| 650 | 4 | |a hypertension | |
| 650 | 7 | |a Angiotensin II Type 1 Receptor Blockers |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Xiao, Guohui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Juanjuan |e verfasserin |4 aut | |
| 700 | 1 | |a He, Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Ou, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Rongqing |e verfasserin |4 aut | |
| 700 | 1 | |a Di, Wencheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zigang |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guoliang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 9(2020), 1 vom: 15. Dez., Seite 757-760 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:1 |g day:15 |g month:12 |g pages:757-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2020.1746200 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 1 |b 15 |c 12 |h 757-760 | ||